Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
July 31 2023 - 7:00AM
Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system (CNS) disorders, today announced
the appointment of Dolan Sondhi, Ph.D., to the Board of Directors
and her appointment to the Nominating and Corporate Governance
Committee. Dr. Sondhi is currently Professor of Research in the
Department of Genetic Medicine at Weill Cornell Medicine.
Additionally, Thomas Woiwode, Ph.D., announced his resignation from
the Board of Directors to focus on his Managing Director role
within Versant Ventures.
"We are thrilled to welcome Dr. Dolan Sondhi to Passage Bio's
Board of Directors," said William Chou, president and chief
executive officer of Passage Bio. "Her extensive experience in AAV
gene therapy research, translational medicine, and
neurodegenerative diseases will be invaluable as we work to bring
life-changing therapies to individuals affected by CNS disorders.
Dr. Sondhi's expertise aligns perfectly with our mission, and we
are excited to have her join our team. I also want to extend my
gratitude to Tom Woiwode for his invaluable contributions to our
Board during his tenure. His dedication and insights have been
instrumental in driving Passage Bio's vision forward, and we thank
him for his service."
Dr. Sondhi is a highly accomplished research scientist with an
impressive career spanning over two decades. Her work has focused
on the development and translation of adeno-associated virus (AAV)
gene therapies for genetic disorders, with a particular emphasis on
CNS diseases. She has made significant contributions to the field
of lysosomal storage diseases, adult neurodegenerative disease
conditions and Friedreich's Ataxia.
"The prospect of joining Passage Bio’s Board of Directors at
this pivotal stage of the company's evolution is incredibly
exciting,” said Dr. Sondhi. “Passage Bio's clinical-stage programs
have shown remarkable promise in early development, and the
company’s unwavering commitment to transforming lives through
groundbreaking gene therapies resonates deeply with my experience
in this field. Together with this accomplished team, I look forward
to ensuring that our promising treatments reach those in need and
make a profound impact on the lives of patients and their
families."
Dr. Sondhi holds a Ph.D. in Chemistry from Brown University and
a Bachelor of Science in Chemistry from St. Stephens College, Delhi
University.
About Passage Bio Passage Bio (Nasdaq: PASG) is
a clinical stage genetic medicines company on a mission to provide
life-transforming therapies for patients with CNS diseases with
limited or no approved treatment options. Our portfolio spans
pediatric and adult CNS indications, and we are currently advancing
clinical programs in GM1 gangliosidosis and frontotemporal dementia
and our preclinical pipeline, including programs in amyotrophic
lateral sclerosis and Huntington’s disease. Based in Philadelphia,
PA, our company has established a strategic collaboration and
licensing agreement with the renowned University of Pennsylvania’s
Gene Therapy Program to conduct our discovery and IND-enabling
preclinical work. Through this collaboration, we have enhanced
access to a broad portfolio of gene therapy candidates and future
gene therapy innovations that we then pair with our deep clinical,
regulatory, manufacturing and commercial expertise to rapidly
advance our robust pipeline of optimized gene therapies. As we work
with speed and tenacity, we are always mindful of patients who may
be able to benefit from our therapies. More information is
available at www.passagebio.com.
For further information, please contact:
Investors:Stuart HendersonPassage
Bio267.866.0114shenderson@passagebio.com
Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2023 to Jul 2024